Anne C.
- Country
- France
- Department
- Hematology
Research Overview
- Phase 2 Study on Zanubrutinib and BGB-11417 Efficacy and Tolerance in Previously Treated Waldenström Macroglobulinemia Patients
- A Phase 3 Randomized Study Comparing Odronextamab and Lenalidomide Versus Rituximab and Lenalidomide in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
- Efficacy and Safety of Golcadomide with R-CHOP Versus Placebo with R-CHOP in High-risk Large B-cell Lymphoma: A Phase 3 Randomized Controlled Trial
Data & Insights
Has run more than one trial at 96 of 296 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular emphasis on developing innovative treatment approaches for these conditions.
- Novel Therapeutic Combinations
- Treatment Duration Optimization
- Disease Monitoring Strategies
Their research explores the effectiveness of targeted therapies and their optimal duration in blood cancer treatment.
Geriatric Oncology
The investigator focuses on developing treatment strategies specifically for elderly patients with hematologic malignancies, particularly those over 70 years of age with CLL or SLL.
- Age-Adapted Treatment Protocols
- Treatment Interruption Studies
- Quality of Life Assessment
Their work addresses the unique challenges and needs of elderly patients receiving cancer treatment.
Precision Medicine
The investigator develops personalized treatment approaches using minimal residual disease (MRD) monitoring to guide therapy decisions.
- Treatment Response Monitoring
- Biomarker-Guided Therapy
- Individualized Duration Strategies
Their research aims to optimize treatment outcomes through precise monitoring and adjustment of therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.